HK1258319A1 - 癌症疗法 - Google Patents

癌症疗法 Download PDF

Info

Publication number
HK1258319A1
HK1258319A1 HK19100687.7A HK19100687A HK1258319A1 HK 1258319 A1 HK1258319 A1 HK 1258319A1 HK 19100687 A HK19100687 A HK 19100687A HK 1258319 A1 HK1258319 A1 HK 1258319A1
Authority
HK
Hong Kong
Prior art keywords
cancer therapy
cancer
therapies
exclusively
prevention
Prior art date
Application number
HK19100687.7A
Other languages
English (en)
Chinese (zh)
Inventor
Doug MCNEEL
Richard LESNIEWSKI
Original Assignee
Madison Vaccines Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madison Vaccines Inc. filed Critical Madison Vaccines Inc.
Publication of HK1258319A1 publication Critical patent/HK1258319A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
HK19100687.7A 2016-02-12 2017-02-10 癌症疗法 HK1258319A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294349P 2016-02-12 2016-02-12
US201662294349P 2016-02-12
US201662404252P 2016-10-05 2016-10-05
US201662404252P 2016-10-05
PCT/US2017/017445 WO2017139628A1 (en) 2016-02-12 2017-02-10 Cancer therapy

Publications (1)

Publication Number Publication Date
HK1258319A1 true HK1258319A1 (zh) 2019-11-08

Family

ID=59088211

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100687.7A HK1258319A1 (zh) 2016-02-12 2017-02-10 癌症疗法

Country Status (8)

Country Link
US (5) US11000578B2 (https=)
EP (1) EP3413927A4 (https=)
JP (2) JP2019512020A (https=)
CN (1) CN108883203A (https=)
AU (1) AU2017217940B2 (https=)
CA (1) CA3013930C (https=)
HK (1) HK1258319A1 (https=)
WO (1) WO2017139628A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
US20220218809A1 (en) * 2018-11-06 2022-07-14 Wisconsin Alumni Research Foundation Ido activity as a marker of tumor immune escape and ido inhibitors as a means of enhancing t cells response to antigen specific vaccine
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3923980A4 (en) * 2019-02-08 2023-01-11 Madison Vaccines Inc. CANCER THERAPY
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
US20230029157A1 (en) * 2019-11-26 2023-01-26 The Regents Of The University Of California Combination therapy for head and neck cancer
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒
EP4175664A2 (en) * 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN118541112A (zh) 2021-12-23 2024-08-23 马斯特里赫特大学 免疫保护型植入式细胞递送装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7179797B2 (en) 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US20070232558A1 (en) 2006-03-31 2007-10-04 Mcneel Douglas G Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
US20090304711A1 (en) 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
AU2008312444B2 (en) * 2007-10-18 2014-02-06 Bavarian Nordic A/S Use of MVA to treat prostate cancer
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
WO2011130742A2 (en) 2010-04-16 2011-10-20 Wisconsin Alumni Research Foundation Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
EP2661622B1 (en) 2011-01-05 2017-11-08 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US10835595B2 (en) * 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CA2955612C (en) * 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
AU2015342939A1 (en) 2014-11-07 2017-05-18 Wisconsin Alumni Research Foundation Targeting DNA vaccines to B cells
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
WO2017139755A1 (en) 2016-02-12 2017-08-17 Rekoske Brian T Cancer therapy

Also Published As

Publication number Publication date
AU2017217940A1 (en) 2018-08-23
JP2019512020A (ja) 2019-05-09
CA3013930C (en) 2025-03-18
EP3413927A4 (en) 2019-11-27
EP3413927A1 (en) 2018-12-19
US20250074987A1 (en) 2025-03-06
AU2017217940B2 (en) 2024-03-21
CA3013930A1 (en) 2017-08-17
US20170182139A1 (en) 2017-06-29
WO2017139628A1 (en) 2017-08-17
JP2022088665A (ja) 2022-06-14
US20240115684A1 (en) 2024-04-11
US20210283232A1 (en) 2021-09-16
US11000578B2 (en) 2021-05-11
US11806391B2 (en) 2023-11-07
CN108883203A (zh) 2018-11-23
US20190030150A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
HK1258319A1 (zh) 癌症疗法
EP3662903A3 (en) Combination therapies
EP4656246A3 (en) Combination therapies for the treatment of cancer
AU2017260425B2 (en) Combination therapy for cancer treatment
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EP3307240A4 (en) Combination therapy for the treatment of cancer
EP3407978A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
HK1221424A1 (zh) 治疗癌症的药物组合
EP3697442A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3258965A4 (en) Combination therapy for cancer treatment
EP4552698A3 (en) Methods of treating prostate cancer
EP3268387A4 (en) Compositions and methods for enhancing the efficacy of cancer therapy
HK1212221A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EP3226901A4 (en) Combination therapy for treatment of cancer
EP3185884A4 (en) Combination therapy for treatment of cancer
TW201613587A (en) Medical treatments based on anamorelin
WO2015179835A3 (en) Mit biomarkers and methods using the same
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3113775A4 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
EP3548007A4 (en) METHOD OF TREATMENT OF CANCER
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
EP3544597A4 (en) THERAPIES FOR THE TREATMENT OF LIDOCAINE AND HYPOKALIEMIC CONDITIONS